Charles River Laboratories | CRL - Assets


Charles River Laboratories reported $7.53B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Agilent USD 13.07B 252M Mar/2026
Align Technology USD 6.42B 103.41M Jun/2026
Bio-Rad Laboratories USD 10.25B 462M Jun/2026
Bruker USD 6.05B 77.8M Jun/2026
Cardinal Health USD 56.69B 1.39B Mar/2026
Charles River Laboratories USD 7.53B 198.16M Jun/2026
Cigna USD 157.08B 3.82B Jun/2026
Concord Medical Services Hldg CNY 6.55B 186.1M Dec/2025
CVS Health USD 253.77B 794M Jun/2026
Danaher USD 92.37B 8.82B Jun/2026
Dentsply International USD 5.23B 200M Mar/2026
Elevance Health USD 126.44B 611M Jun/2026
Humana USD 57.2B 1.92B Jun/2026
Illumina USD 6.65B 91M Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
IQVIA Holdings USD 29.88B 206M Jun/2026
Laboratory Of America USD 18.53B 554.8M Jun/2026
Lakefront Biotherapeutics EUR 3.37B 34.09M Mar/2026
Lonza CHF 18.97B 164M Dec/2025
McKesson USD 88.33B 6.01B Jun/2026
Merck EUR 53.07B 1.54B Mar/2026
Mettler Toledo International USD 3.67B 2.03M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Quest Diagnostics USD 16.94B 266M Jun/2026
Revvity USD 12.05B 49.24M Jun/2026
Thermo Fisher Scientific USD 113.17B 107M Jun/2026
United Therapeutics USD 7.22B 505.9M Jun/2026
UnitedHealth USD 309.73B 2.92B Jun/2026
Veradigm USD 1.5B 185.94M Dec/2022
Waters USD 24.75B 220M Jun/2026
West Pharmaceutical Services USD 4.08B 33.4M Jun/2026